Objective: To provide real-world data on caregiver and physician perceptions of the advantages and disadvantages of rotigotine transdermal patch (Neupro * ) versus oral Parkinson's Disease (PD) medication.

Methods: Cross-sectional, non-interventional study in routine clinical practice in Germany (NCT01330290). Patients had PD with documented need for care, and had received rotigotine transdermal patch as add-on to oral PD treatment for ≥1 month. Caregivers/nurses and physicians assessed rotigotine transdermal patch versus oral PD medications using questionnaires. Specific questions regarding the possible benefits of transdermal application were asked and comprised questions on: swallowing dysfunction, nausea/vomiting, monitoring therapy, once daily application, application independently from meals, application to sleeping patients, caregiving efforts (caregivers only) and clinical aspects (physicians only). Each question was assessed on a 5 point scale ranging from -2 (major disadvantage) to 2 (major advantage) compared with oral treatment. Primary outcomes were mean total scores of all questions for caregivers/nurses and physicians who provided responses for ≥4 questions. As there are no validated tools to assess physician/caregiver preference in the PD setting, there is no reference against which the current findings can be compared; this study serves to pilot the questionnaires.

Results: Questionnaire responses from 128 caregivers/nurses and 41 physicians were documented for 147 patients. One hundred (68%) patients had a caregiving family member; 40 (27%) were cared for by a nurse. Mean PD duration was 8.2 (SD 6.3) years; 136 (93%) patients were taking levodopa. Mean total score of caregivers'/nurses' questionnaires was 1.32 (SD 0.67) and of physicians' questionnaires was 1.46 (0.32) indicating a perceived advantage of rotigotine transdermal patch over oral PD therapy. Mean scores for individual questions were in the range 1.03-1.54 for caregivers/nurses and 1.15-1.87 for physicians. When given a choice about rationale to prescribe, physicians cited pharmaceutical form (patch) in 139 (95%) cases and active agent (rotigotine) in 89 (61%) cases.

Conclusion: Caregivers/nurses and physicians perceived advantages with rotigotine transdermal patch compared to an oral PD medication as add-on therapy in patients with PD; advantages were observed in aspects of medical treatment as well as in everyday situations of caregiving of PD patients.

Download full-text PDF

Source
http://dx.doi.org/10.1185/03007995.2015.1030376DOI Listing

Publication Analysis

Top Keywords

rotigotine transdermal
24
transdermal patch
24
caregivers/nurses physicians
16
versus oral
12
patch versus
8
oral parkinson's
8
parkinson's disease
8
oral treatment
8
patients caregiving
8
compared oral
8

Similar Publications

Article Synopsis
  • The study aimed to compare the skin adhesion of a new rotigotine transdermal patch (ROT-TDS) to an existing product for patients with Parkinson's disease (PD).
  • Research included pharmacokinetic testing on healthy adults and a trial on PD patients to assess adhesion and safety.
  • Results showed that ROT-TDS had similar effectiveness and safety as the reference patch but also demonstrated better skin adhesion, with a higher percentage of patches staying adhered through the dosing period.
View Article and Find Full Text PDF

Introduction: This guideline establishes clinical practice recommendations for treatment of restless legs syndrome (RLS) and periodic limb movement disorder (PLMD) in adults and pediatric patients.

Methods: The American Academy of Sleep Medicine (AASM) commissioned a task force of experts in sleep medicine to develop recommendations and assign strengths based on a systematic review of the literature and an assessment of the evidence using the grading of recommendations assessment, development, and evaluation methodology. The task force provided a summary of the relevant literature and the certainty of evidence, the balance of benefits and harms, patient values and preferences, and resource use considerations that support the recommendations.

View Article and Find Full Text PDF

Chronic endothelial dopamine receptor stimulation improves endothelial function and hemodynamics in autosomal dominant polycystic kidney disease.

Kidney Int

December 2024

University Rouen Normandie, Institut national de la santé et de la recherche médicale (INSERM) U1096, Endothélium, Valvulopathies, Insuffisance cardiaque (EnVI), Rouen, France; Department of Pharmacology, Centre Hospitalier Universitaire (CHU) Rouen, Rouen, France; Centre d'Investigation CLinique-Centre de Ressources Biologiques (CIC-CRB) 1404, Rouen, France. Electronic address:

Article Synopsis
  • The study explores how altered endothelial flow sensitivity related to polycystin deficiency contributes to hypertension in autosomal dominant polycystic kidney disease (ADPKD) patients.
  • Nineteen ADPKD patients were treated with the dopamine receptor agonist rotigotine, showing that a higher dose significantly improved nitric oxide release and endothelial function without major changes in overall blood pressure.
  • The findings suggest that targeting endothelial dopamine receptors could be a promising new treatment strategy to mitigate cardiovascular issues linked with ADPKD.
View Article and Find Full Text PDF

Allergic contact dermatitis to sodium metabisulphite in a rotigotine transdermal therapeutic system.

Contact Dermatitis

December 2024

Serviço de Dermatologia, Unidade Local de Saúde Santa Maria, Centro Académico de Medicina de Lisboa, Lisboa, Portugal.

View Article and Find Full Text PDF

Background: A Non-Ergot Dopamine Agonist (NEDA) rotigotine has been designed as a new transdermal drug delivery system.

Aim: To maintain optimum homogeneity in drug content, the rotigotine transdermal patch was developed utilizing a solvent casting technique.

Methods: The characteristics of a transdermal patch, including patch weight, folding endurance, patch thickness, surface morphology, tensile strength, swelling rate, surface pH, in vitro release studies, water retention rate, uniformity of drug content, and ex-vivo permeation studies, were determined.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!